Navigation Links
Bacterin International Completes $3 Million Private Placement

BELGRADE, Mont., Feb. 12 /PRNewswire/ -- Bacterin International, Inc. (Bacterin), a developer of biological scaffolds for orthopedic indications, today announced the completion of a $3 million private placement of Secured Convertible Promissory Notes led by Middlebury Securities, LLC.

Proceeds from the raise will be used to repay approximately $800,000 of existing debt and the remainder will be used to expand the Company's sales and marketing effort and general working capital purposes.

Commenting on the successful capital raise, Guy Cook, Bacterin's founder and CEO, said, "We are very pleased with the investor reception of our business model.  Over the last nine years, Bacterin's team of highly experienced professionals have worked diligently developing and perfecting its technology and creating a facility that would position the company to effectively market and deliver innovative products to the orthopedics industry.  Our OsteoSponge® product, made from demineralized cancellous bone and optimized to preserve bone morphogenetic proteins, provides surgeons with an osteoinductive scaffold that is highly economical with superior handling and wicking properties."

Mr. Cook continued, "The additional capital raised by Middlebury Securities will enable Bacterin to expand its sales effort at a time when the medical industry is eager for efficacious products that are cost-effective.  The investor base the Middlebury Group introduced to our company is comprised of seasoned investors who recognize the potential for Bacterin's proprietary technology.  We look forward to our relationship with these new investors and Middlebury, while we focus on delivering results."

About Bacterin International

Bacterin International, Inc. designs, tests and licenses bioactive coatings for medical applications. The Company incorporates a variety of classes of active agents into coatings: antimicrobial, analgesic, anti-thrombotic, anti-inflammatory, and other drugs suitable for medical applications.  Bacterin also produces and markets innovative biologic alografts for transplantation.  The Company's products, OsteoSponge®, OsteoSpongeSC® and OsteoWrap™, are made from demineralized bone that is malleable and flexible, which enables more efficient and precise handling. It also markets OsteoLock®, used in spine surgery, minimizes graft back-out, and increases osteoinductivity.  Headquartered in Belgrade, Montana, Bacterin operates a 32,000 sq. ft., state-of-the-art, full compliant and FDA registered facility, equipped with five Class 100 clean rooms.

This news release contains disclosures that are forward-looking statements. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions. These forward-looking statements are based on current expectations or beliefs and include, but are not limited to, statements about maximizing gross profit dollars, the Company's potential to achieve top and bottom line growth. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the company's ability to meet its obligations under existing and anticipated contractual obligations; the company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability and willingness of third-party manufacturers to timely and cost-effectively fulfill orders from the company; the ability of the company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the company' ability to obtain financing as and when needed; changes in consumer demands and preferences; the company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. The company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE Bacterin International, Inc.



SOURCE Bacterin International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. International Merchant Advisors, Inc. Offers to Invest in Pharmaceutical Chain
2. DATATRAK International and PFC Pharma Focus to Co-Sponsor eClinical Solutions Seminar in Tel Aviv
3. CORD:USE Cord Blood Bank Featured Internationally on CNN en Espanol
4. Mettler-Toledo International Inc. Reports Fourth Quarter 2009 Results
5. Cayman Island National Insurance Company Reaches Service Agreement with Mobile Surgery International
6. The International Negative Pressure Wound Therapy Expert Panel to Announce Results of Inaugural Symposium in Hamburg
7. International NPWT Expert Panel Convenes in Hamburg
8. Chindex International to Report Third Quarter Fiscal Year 2010 Financial Results
9. PRA International Formalizes Partnership with Oncopartners and IBPC
10. DATATRAK International, Inc. Announces Year-End Backlog
11. International Drug & Explosives Detection Firm IDenta Corp Announces that the TNT/PETN/RDX/NITRATE Test Kit can be used as a General Screening Explosive Identifier
Post Your Comments:
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
Breaking Medicine News(10 mins):